EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Changes of endogenous erythropoietin level and iron status during a 30-month hemodialysis treatment of a group of patients



Changes of endogenous erythropoietin level and iron status during a 30-month hemodialysis treatment of a group of patients



International Urology and Nephrology 33(3): 541-546



In our earlier paper (1) we found that among 50 hemodialysis patients (HD pts) 48% (24 pts) control anemia with hemoglobin (Hb) concentration>9.5 g/dl and hematocrit (Hct)>30% without recombinant human erythropoietin (rHuEpo) therapy. These HD pts had significantly higher mean endogenous erythropoietin (eEpo) level and lower iron reserves (IR) than HD pts who need rHuEpo therapy. The aim of this study was to judge whether the possibility to control anemia in pts not requiring rHuEpo therapy changes during a 30-month HD treatment. Serum eEpo and ferritin were measured every 6 months. After 30 months of HD treatment 18 pts remained in this group - 5 pts died, I underwent transplantation. During the study period 4/18 pts permanently had a very low level of eEpo (under detection limit), 7/18 had the level of eEpo within normal range for healthy control, 7/18 pts had a high level of eEpo (up to 3 times higher than the mean for healthy control). Pts who had the highest level of eEpo had the lowest IR. After 30 months IR were significantly lower than at the beginning of observation (292+-87 vs 143+-127 mg). Important negative correlation between eEpo and IR was observed throughout the whole period of study: r=-0.4820, p<0.02 at the start of the study, and r=-0.6126, p<0.007 after 30 months of treatment. The study shows that the possibility to control anemia in pts not treated with rHuEpo did not change significantly during 30 months of HD treatment. Endogenous Epo level in HD pts not treated with rHuEpo varied between different pts: it was permanently low in some pts, permanently high in others and stayed normal in remaining pts.

(PDF emailed within 0-6 h: $19.90)

Accession: 010297067

Download citation: RISBibTeXText

DOI: 10.1023/a:1019558511411



Related references

Changes of endogenous erythropoietin level and iron status during a 30-month hemodialysis treatment of a group of patients. International Urology and Nephrology 33(3): 541-546, 2002

Changes in serum erythropoietin /EPO/ and iron reserves /IR/ during a 30-month haemodialysis /HD/ treatment of a group of patients. Nephrology Dialysis Transplantation 12(9): A189, 1997

Diagnostic power of iron status markers in detecting functional iron deficiency in hemodialysis patients on erythropoietin. Nephrology Dialysis Transplantation 15(9): A157, September, 2000

Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum. Gaoxiong Yi Xue Ke Xue Za Zhi 7(3): 126-135, 1991

Role of endogenous erythropoietin in the hematopoietic response to iron administration in hemodialysis patients. Journal of the American Society of Nephrology 6(3): 571, 1995

Correlation between erythropoietin sensitivity and parameters of iron status in hemodialysis patients. Nephrology Dialysis Transplantation 15(9): A157, September, 2000

Serum erythropoietin concentrations and iron status in patients on chronic hemodialysis. Clinical Chemistry 38(2): 199-203, 1992

The influence of aluminum and iron status on serum erythropoietin concentrations in hemodialysis patients. Nephrology Dialysis Transplantation 10(6): 1050, 1995

Iron status and low dose intravenous FeGluconate in hemodialysis patients on maintenance erythropoietin. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 272A, Sept, 1998

Effects of treatment of anemia on endogenous secretion of erythropoietin epo in hemodialysis hd patients. Journal of the American Society of Nephrology 2(3): 389, 1991

Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin. International Urology and Nephrology 46(1): 161-167, 2014

Maintenance iron dextran treatment in hemodialysis patients on erythropoietin. Journal of the American Society of Nephrology 3(3): 432, 1992

A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases 30(4): 495-500, 1997

A six month study of low-dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients. Journal of the American Society of Nephrology 7(9): 1490, 1996